SCHEMBL2481632

SCHEMBL2481632

CCCCCc1cc(N)ccc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.54
GABRD O14764 2/20 0.54
GABRA1 P14867 2/20 0.54
GABRB1 P18505 2/20 0.54
GABRG2 P18507 2/20 0.54
GABRB3 P28472 2/20 0.54
GABRA5 P31644 2/20 0.54
GABRA3 P34903 2/20 0.54
GABRA2 P47869 2/20 0.54
GABRB2 P47870 2/20 0.54
GABRA4 P48169 2/20 0.54
GABRE P78334 2/20 0.54
GABRA6 Q16445 2/20 0.54
GABRG1 Q8N1C3 2/20 0.54
GABRG3 Q99928 2/20 0.54
GABRQ Q9UN88 2/20 0.54
PPARA Q07869 3/20 0.51
HPSE Q9Y251 2/20 0.49
PPARG P37231 2/20 0.48
KAT8 Q9H7Z6 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9068780 0.98 PPARA (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL6112733 0.98 PPARA (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9068637 0.98 PPARA (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4327627 0.98 PPARA (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL240794 0.95 GABRP (0.59) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31117550 0.95 GABRP (0.59) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL343331 0.92 ALDH1A1 (0.55) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL29632107 0.92 ALDH1A1 (0.55) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30833194 0.90 MAPT (0.53) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1931833 0.88 MAPT (0.52) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1595936-B1 COMPOSITION FOR EXTERNAL USE VITAMIN C60 BIORES CORP (JP) 2011-10-19 EP claimed
US-20250057872-A1 INNATE IMMUNOMODULATORY EFFECT OF GINSENG BERRY POLYSACCHARIDES IN IMMUNOCOMPROMISED CONDITIONS Gangneung-Wonju National University Industry Academy Cooperation Group (KR) 2025-02-20 US disclosed
US-20240285714-A1 COMPOSITION FOR ANTI-INFLAMMATORY, ANTIOXIDANT, ANTI-WRINKLE OR HAIR HEALTH PROMOTION CONTAINING EXTRACT MIXTURE OF ZIZIPHUS JUJUBA MILLER, CITRUS UNSHIU PEEL AND ACORUS CALAMUS AS ACTIVE INGREDIENT INDUSTRY-ACADEMIC COOPERATION FOUNDATION DAEGU HAANY UNIVERSITY (KR) 2024-08-29 US disclosed
US-11518735-B2 Pseudoceramide compound with improved stability and composition comprising same AE KYUNG INDUSTRIAL CO., LTD. (KR) 2022-12-06 US disclosed
US-20200354309-A1 NOVEL PSEUDOCERAMIDE COMPOUND WITH IMPROVED STABILITY AND COMPOSITION COMPRISING SAME AE KYUNG INDUSTRIAL CO., LTD (KR) 2020-11-12 US disclosed
US-10722548-B2 Method of preparing lyophilizate of Taheebo alcohol extract COSMAX NBT, INC. (KR) 2020-07-28 US disclosed
US-10695314-B2 Antimicrobial composition containing 7,10-epoxyoctadeca-7,9-dienoic acid as active ingredient KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2020-06-30 US disclosed
US-20190167746-A1 METHOD OF PREPARING LYOPHILIZATE OF TAHEEBO ALCOHOL EXTRACT NUTRIBIOTECH (KR) 2019-06-06 US disclosed
US-20190133989-A1 ANTIMICROBIAL COMPOSITION CONTAINING 7,10-EPOXYOCTADECA-7,9-DIENOIC ACID AS ACTIVE INGREDIENT KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2019-05-09 US disclosed
US-10233143-B2 Pseudoceramide compound, and external use skin preparation composition containing same AE KYUNG INDUSTRIAL CO., LTD (KR) 2019-03-19 US disclosed
US-20160303146-A1 INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS TABACZYNSKI DAVID A (US) 2016-10-20 US disclosed
WO-2015089349-A1 INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS TABACZYNSKI DAVID A (US) 2015-06-18 WO disclosed
WO-2015084721-A1 INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS TABACZYNSKI DAVID A (US) 2015-06-11 WO disclosed
US-8747816-B2 UV-photoprotective compositions comprising diebenzoylmethane screening agents and silicon-containing s-triazine compounds substituted with two aminobenzoate or aminobenzamide groups L'OREAL (FR) 2014-06-10 US disclosed
US-20120129838-A1 Composition for Preventing and Treating Alopecia Disorder Containing Morgalanthamine Compounds as an Active Ingredient THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (KR) 2012-05-24 US disclosed
US-20080145324-A1 UV-photoprotective compositions comprising diebenzoylmethane screening agents and silicon-containing s-triazine compounds substituted with two aminobenzoate or aminobenzamide groups L'OREAL (FR) 2008-06-19 US disclosed
US-5482986-A ULTRAVIOLET RADIATION ABSORBER FOR THERMOPLASTIC RESINS; COLORLESS, HEAT RESISTANCE MITSUI TOATSU CHEMICALS, INC. (JP) 1996-01-09 US disclosed
EP-0635504-A1 Benzopyran compound and use of the same MITSUI TOATSU CHEMICALS, Inc. (JP) 1995-01-25 EP disclosed
US-RE28806-E Liquid crystal compositions XEROX CORPORATION (US) 1976-05-11 US disclosed
US-3931041-A LIQUID CRYSTAL COMPOSITIONS XEROX CORPORATION (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129838-A1 Composition for Preventing and Treating Alopecia Disorder Containing Morgalanthamine Compounds as an Active Ingredient MITF, GLA, GALNT3 GABRP 4401/4885GABRD 3493/4885GABRA1 4008/4885
US-20080145324-A1 UV-photoprotective compositions comprising diebenzoylmethane screening agents and silicon-containing s-triazine compounds substituted with two aminobenzoate or aminobenzamide groups TST, TYR, DDT GABRP 3329/4885GABRD 2455/4885GABRA1 3346/4885
US-11518735-B2 Pseudoceramide compound with improved stability and composition comprising same CERS2, ASAH2, ASAH1 GABRP 4619/4885GABRD 4836/4885GABRA1 4770/4885
US-20200354309-A1 NOVEL PSEUDOCERAMIDE COMPOUND WITH IMPROVED STABILITY AND COMPOSITION COMPRISING SAME CERS2, ASAH2, CERT1 GABRP 4566/4885GABRD 4835/4885GABRA1 4746/4885
US-10695314-B2 Antimicrobial composition containing 7,10-epoxyoctadeca-7,9-dienoic acid as active ingredient CYP51A1, IL17A, ELOVL5 GABRP 3054/4885GABRD 978/4885GABRA1 2857/4885
US-20160303146-A1 INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS GGPS1, FDPS, COASY GABRP 1928/4885GABRD 2651/4885GABRA1 2694/4885
US-20190133989-A1 ANTIMICROBIAL COMPOSITION CONTAINING 7,10-EPOXYOCTADECA-7,9-DIENOIC ACID AS ACTIVE INGREDIENT CYP51A1, IL17A, ELOVL5 GABRP 3054/4885GABRD 978/4885GABRA1 2857/4885
US-10233143-B2 Pseudoceramide compound, and external use skin preparation composition containing same CERS2, CERT1, ACER2 GABRP 3953/4885GABRD 4747/4885GABRA1 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.